GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stayble Therapeutics AB (OSTO:STABL) » Definitions » 3-Year FCF Growth Rate

Stayble Therapeutics AB (OSTO:STABL) 3-Year FCF Growth Rate : 0.00% (As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Stayble Therapeutics AB 3-Year FCF Growth Rate?

Stayble Therapeutics AB's Free Cash Flow per Share for the three months ended in Sep. 2023 was kr-0.14.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 7 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Stayble Therapeutics AB was -3.60% per year. The lowest was -74.10% per year. And the median was -38.85% per year.


Competitive Comparison of Stayble Therapeutics AB's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Stayble Therapeutics AB's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Stayble Therapeutics AB's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Stayble Therapeutics AB's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Stayble Therapeutics AB's 3-Year FCF Growth Rate falls into.



Stayble Therapeutics AB 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Stayble Therapeutics AB  (OSTO:STABL) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Stayble Therapeutics AB 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Stayble Therapeutics AB's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Stayble Therapeutics AB (OSTO:STABL) Business Description

Traded in Other Exchanges
Address
Medicinaregatan 8a, Gothenburg, SWE, SE-413 90
Stayble Therapeutics AB is a clinical-stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and analgesics. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. The company's injection treatment, STA363, is expected to correct the underlying cause of disc-related low back pain by affecting the two main causative factors namely instability of the disc and prevention of leakage of inflammatory mediators from the disc center.

Stayble Therapeutics AB (OSTO:STABL) Headlines

No Headlines